UCB SA |
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 77,77 USD | -0,71 % |
|
-0,04 % | +78,37 % |
| 24.06. | Argenx SE: zieht Bel20 nach Zulassung für Vyvgart nach oben |  |
| 20.06. | UCB : Kepler Cheuvreux ist neutral | ZM |
Kurzporträt
Mitarbeiterzahl: 8 767
Umsatz nach Geschäftsbereich
| EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
Biopharmaceuticals
100,0
%
| 5 140 | 100,0 % | 4 867 | 100,0 % | -5,31 % |
Umsatz je Region
| EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
United States
50,4
%
| 2 902 | 56,5 % | 2 454 | 50,4 % | -15,44 % |
Other Countries
11,4
%
| 507 | 9,9 % | 554 | 11,4 % | +9,27 % |
Europe - Other
7,5
%
| 348 | 6,8 % | 365 | 7,5 % | +4,89 % |
Germany
6,4
%
| 330 | 6,4 % | 310 | 6,4 % | -6,06 % |
Japan
5,5
%
| 324 | 6,3 % | 269 | 5,5 % | -16,98 % |
Spain
4,6
%
| 213 | 4,1 % | 224 | 4,6 % | +5,16 % |
France (including French Territories)
3,3
%
| 169 | 3,3 % | 162 | 3,3 % | -4,14 % |
China
3,1
%
| 159 | 3,1 % | 151 | 3,1 % | -5,03 % |
Italy
2,9
%
| 154 | 3,0 % | 143 | 2,9 % | -7,14 % |
United Kingdom and Ireland
2,7
%
| 151 | 2,9 % | 133 | 2,7 % | -11,92 % |
Belgium
1,1
%
| 49 | 1,0 % | 52 | 1,1 % | +6,12 % |
Global
1,0
%
| -167 | -3,2 % | 50 | 1,0 % | -129,94 % |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
| Chief Executive Officer | 65 | 01.06.11 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 57 | 01.07.20 |
| Chief Tech/Sci/R&D Officer | 63 | 01.10.17 | |
| Chief Tech/Sci/R&D Officer | 65 | 01.01.19 | |
| Chief Tech/Sci/R&D Officer | 63 | 01.09.06 | |
Antje Witte
IRC | Investor Relations Contact | - | - |
Dominique Baeten
PRN | Corporate Officer/Principal | - | - |
Thomas Debeys
AUD | Comptroller/Controller/Auditor | - | - |
Jean Fleurial
HRO | Human Resources Officer | 59 | 01.09.17 |
| Corporate Officer/Principal | - | 01.03.94 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
| Director/Board Member | 66 | 28.04.16 | |
Dame Davies
BRD | Director/Board Member | 73 | 01.01.14 |
| Chief Executive Officer | 65 | 01.06.11 | |
Cyril Janssen
BRD | Director/Board Member | 53 | 01.01.15 |
Jonathan Peacock
CHM | Chairman | 66 | 01.01.21 |
Maëlys Castella
BRD | Director/Board Member | 58 | 01.01.23 |
| Director/Board Member | 54 | 24.04.14 | |
| Director/Board Member | 53 | 01.01.01 | |
Susan Gasser
BRD | Director/Board Member | 69 | 01.01.21 |
Pierre Gurdjian
BRD | Director/Board Member | 63 | 28.04.16 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 1 | 194 505 658 | 119 501 352 ( 61,44 %) | 4 755 075 ( 2,445 %) | 61,44 % |
Unternehmensbesitz
| Name | Aktien | % | Bewertung |
|---|---|---|---|
UCB 2,44% | 4 755 075 | 2,44% | 706 850 077 $ |
Unternehmenskontakt
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
UCB Manufacturing Ireland Ltd.
| |
UCB Ventures SA
|
Investment Managers
|
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. |
Pharmaceuticals: Major
|
UCB Ventures Belgium SA
|
Investment Managers
|
UCB Pharma GmbH
 UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. |
Pharmaceuticals: Major
|
UCB Pharma SA (Belgium)
 UCB Pharma SA (Belgium) Pharmaceuticals: MajorHealth Technology UCB Pharma SA discovers and develops biopharmaceutical products. It is a biopharmaceutical company focuses on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. The company is headquartered in Brussels, Belgium. |
Pharmaceuticals: Major
|
Ucb Belgium SA
 Ucb Belgium SA Pharmaceuticals: MajorHealth Technology Part of UCB SA, UCB Belgium SA is a Belgian bio-pharmaceutical company that focuses on neurology and immunology. The company is based in Brussels, Belgium. The company was founded by Emmanuel Janssen. |
Pharmaceuticals: Major
|
UCB Pharma Ltd.
 UCB Pharma Ltd. Pharmaceuticals: MajorHealth Technology UCB Pharma Ltd. operates as a biopharmaceutical company. The firm focuses on developing medicines for severe diseases in Immunology and CNS. The company is headquartered in Slough, the United Kingdom. |
Pharmaceuticals: Major
|
UCB Biopharma SRL
 UCB Biopharma SRL Medical DistributorsDistribution Services Part of UCB SA, UCB Biopharma SRL is a Belgian pharmaceutical company founded in 2013. The company is based in Brussels, Belgium. UCB Biopharma specializes in the development of treatments for various medical conditions, including axial spondyloarthritis, psoriatic arthritis, and other health issues. The company also manages the UCB Community Health Fund and holds an annual shareholders meeting. |
Medical Distributors
|
Sektor
Umsatz je Region
Verlauf des Gewinns je Aktie
| % 1. Jan. | Kap. | |
|---|---|---|
| +7,40 % | 101 Mrd. | |
| +8,42 % | 42,18 Mrd. | |
| -13,04 % | 32,26 Mrd. | |
| -10,92 % | 16,06 Mrd. | |
| +1,93 % | 14,45 Mrd. | |
| -6,77 % | 12,01 Mrd. | |
| +177,16 % | 10,71 Mrd. | |
| +4,12 % | 8,89 Mrd. | |
| -56,13 % | 8,83 Mrd. |
- Börse
- Aktien
- 852738 Aktie
- A14WZY Aktie
- Unternehmen UCB SA
